Fortress Biotech, Inc. Annual report pursuant to Section 13 and 15(d)

Revenues from Contracts and Significant Customers (Narrative) (Details) $ in Millions	12 Months Ended		24 Months Ended
	Dec. 31, 2023 customer	Dec. 31, 2022 customer	Dec. 31, 2023 USD ($)
Disaggregation of Revenue [Line Items]
Payments of milestones \| $			$ 0.5
Dermatology Products Sales \| Customer Concentration Risk \| Revenue
Disaggregation of Revenue [Line Items]
Number of customers	0	0
Dermatology Products Sales \| Customer Concentration Risk \| Accounts Receivable
Disaggregation of Revenue [Line Items]
Number of customers	1	2
Dermatology Products Sales \| Customer One \| Customer Concentration Risk \| Accounts Receivable
Disaggregation of Revenue [Line Items]
Concentration risk, percentage		16.70%
Dermatology Products Sales \| Customer Two \| Customer Concentration Risk \| Accounts Receivable
Disaggregation of Revenue [Line Items]
Concentration risk, percentage	13.00%	10.40%